Evidence map›Paper›PMID 29719433›Full record

ArticleCurrent oncology (Toronto, Ont.)2018

Male Oncology Research and Education program for men at high risk for prostate cancer.

J Lorentz, S K Liu, D Vesprini

Abstract read
In one paragraph

Article in Current oncology (Toronto, Ont.), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Screening guidelines for individuals at increased risk for prostate cancer.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2024
    Review
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

J LorentzRadiation Oncology, Sunnybrook Odette Cancer Centre, Toronto, ON.
S K LiuRadiation Oncology, Sunnybrook Odette Cancer Centre, Toronto, ON.
D VespriniRadiation Oncology, Sunnybrook Odette Cancer Centre, Toronto, ON.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Three groups of men are at high risk of developing prostate cancer: men with a strong family history of prostate cancer, men of West African or Caribbean ancestry, and men with a germline pathogenic variant in a prostate cancer-associated gene. Despite the fact that those men constitute a significant portion of the male population in North America, few recommendations for prostate cancer screening specific to them have been developed. For men at general population risk for prostate cancer, screening based on prostate-specific antigen (psa) has remained controversial despite the abundance of literature on the topic. As a result, recommendations made by major screening authorities are inconsistent (ranging from no psa screening to baseline psa screening at age 45), allowing physicians to pick and choose how to screen their patients. The Male Oncology Research and Education (more) program is an observational research program that serves as an academic platform for multiple research foci. For its participants, serum and dna are biobanked, medical information is collected, and contact for relevant research-related opportunities is maintained. This research program is paired with a specialized clinic called the more clinic, where men at high risk are regularly screened for prostate cancer in a standard approach that includes physical examination and serum psa measurement. In this article, we describe the goals, participant accrual to date, and projects specific to this unique program.

Indexed as

Ambulatory Care FacilitiesBiological Specimen BanksBiomedical ResearchEarly Detection of CancerGenetic Predisposition to DiseaseHumansKallikreinsMaleObservational Studies as TopicOntarioProgram EvaluationProstate-Specific AntigenProstatic NeoplasmsRisk FactorsKallikreinsKLK3 protein, humanProstate-Specific Antigenbiobankscancer geneticshigh-risk diseaseProstate cancerpsaresearch programsscreening

Identifiers

PMID29719433
PMCPMC5927788

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.